2nd edition. The purpose of this document is to present updated standardized protocols that P. falciparum-endemic countries can use to determine the prevalence of parasites with pfhrp2/3 gene deletions causing negative HRP2 RDT results among symptomatic falciparum patients. The findings should be us...ed to guide RDT selection; more specifically when to shift away from exclusive use of HRP2 to detect P. falciparum infections.
more
The WHO Mekong Malaria Elimination (MME) programme hosted a 3-day meeting on 15–17 November 2023 in Siem Riep, Cambodia for representatives from national malaria programmes, research institutions, partners, donors, WHO and UN agencies. The meeting provided a forum to discuss surveillance systems, ...the future priorities for the WHO Malaria Elimination Database and areas of improvement for data sharing, the efficacy of antimalarial drugs, progress made in malaria elimination, and challenges raised by P. vivax elimination.
more
This practical document is available to support programmes and partners to design and implement risk communication strategies to achieve high uptake of malaria vaccination.
Preferred product characteristics and clinical development considerations
Presentation OPT-SMC malaria vaccine workshop - Jan 2023
Brief Introduction Malaria Vaccine Training. For countries planning malaria vaccine introduction, WHO has developed training packages of slide sets on key topics for health workers in English and French that can be downloaded and customized to meet specific country needs:
Programa de Implementação da Vacina contra a Malária: 2019 – 2023.
The aim of this protocol is to support the conduct of entomological comparative efficacy assessments for vector control products and the associated non-inferiority analysis. This evidence is used to inform discussions within the guidelines development context as to whether a new vector control prod...uct should be considered as covered by one or more existing WHO recommendations or not. Alternatively, the evidence may inform the extension of an existing WHO recommendation or the development of a new one, provided that non-inferiority is demonstrated
more
In recent decades we have seen progressive changes to global climate patterns caused by anthropogenic impacts on the environment. These are likely to directly and indirectly affect human health, and are projected to continue and potentially
accelerate into the future. Neglected tropical diseases (N...TDs) and malaria are potentially particularly sensitive to these changes as they
are prevalent amongst vulnerable populations
in countries expected to experience the greatest
environmental change in the coming decade.
more
Available in English, French an Spanish. The Malaria Threats Map is an interactive data platform which provides a geographic overview of the status of the 4 biological threats to malaria control and elimination
This training module on malaria case management has been developed to support the staff involved in malaria control and elimination programmes in the effective organization of malaria diagnosis and case management services
This video explores the impact of rapid urbanisation on the transmission of malaria, highlighting that, although the burden of malaria remains highest in rural areas, the majority of people in malaria-endemic countries will soon reside in urban areas. It explains how well-planned urbanisation can re...duce malaria by improving access to healthcare and infrastructure, whereas rapid, unplanned urban growth may increase the risk, particularly among the urban poor.
more
Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV prevention overall, as it allows people to choose a method that they prefer.
In this guideline, WHO recommends an offering long-acting injectable lenacapavir (LEN...) as an additional HIV prevention choice, as part of combination HIV prevention approaches. LEN, administered twice a year as PrEP, has been shown to be highly effective at reducing the risk of HIV acquisition. In this guideline, WHO also recommends using HIV rapid diagnostic tests (RDTs) for individuals initiating or continuing long-acting injectable PrEP, such as LEN and long acting injectable cabotegravir (CAB-LA). Flexible HIV testing approaches are essential for ensuring that testing does not become a barrier to accessing or continuing PrEP, including long-acting injectable options.
more
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex B
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex C